A Phase II Study of High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Brief description of study

The purpose of this study is to determine the rate of graft-versus-host disease (GvHD) for patients receiving bortezomib, known commercially as Velcade®, and cyclophosphamide, known as Cytoxan®. These medications will be given as standard of care, as part of your transplant. Both of these medications are FDA approved for other indications. Cyclophosphamide has been extensively studied for the prevention of GvHD. Cyclophosphamide inhibits rapidly dividing cells, specifically T cells, that are involved in the development of GvHD. Bortezomib has been shown to inhibit the development of GVHD. It modulates immune reaction and inhibits the maturation of cells involved in the initiation of GvHD process.

Clinical Study Identifier: s18-01185
ClinicalTrials.gov Identifier: NCT03945591

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.